2017 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
John V. Heymach focuses on Cancer research, Lung cancer, Cancer, Internal medicine and Oncology. His biological study spans a wide range of topics, including Molecular biology, KRAS, Immunology and Epidermal growth factor receptor. His study in Lung cancer is interdisciplinary in nature, drawing from both Epithelial–mesenchymal transition, Targeted therapy, Randomized controlled trial and Adenocarcinoma.
His work carried out in the field of Cancer brings together such families of science as Blockade, CD8 and Pathology. His Internal medicine research incorporates themes from Surgery and Drug resistance. John V. Heymach interconnects Clinical trial, Phases of clinical research, Vandetanib, Carcinoma and Docetaxel in the investigation of issues within Oncology.
Cancer research, Internal medicine, Lung cancer, Oncology and Cancer are his primary areas of study. His Cancer research study integrates concerns from other disciplines, such as Immunology, Immune system, Pathology, KRAS and Adenocarcinoma. His Chemotherapy, Radiation therapy, Phases of clinical research and Vandetanib study in the realm of Internal medicine interacts with subjects such as In patient.
The study incorporates disciplines such as Targeted therapy, Carcinoma and Immunotherapy in addition to Lung cancer. His Oncology research incorporates elements of Biomarker, Clinical trial, Lung and Cytokine. The concepts of his Cancer study are interwoven with issues in PI3K/AKT/mTOR pathway and Angiogenesis.
John V. Heymach spends much of his time researching Lung cancer, Internal medicine, Cancer research, Oncology and Cancer. His work in the fields of Lung cancer, such as Non small cell, overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2. His Internal medicine study frequently links to related topics such as Gastroenterology.
His Cancer research study also includes fields such as
His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer research and Immunotherapy. His studies deal with areas such as Immunohistochemistry, Exome sequencing, Carcinoma, Metastasis and Lung as well as Lung cancer. His biological study deals with issues like Gastroenterology, which deal with fields such as Prospective cohort study and Progression-free survival.
His studies in Oncology integrate themes in fields like Pembrolizumab, Biopsy, Clinical trial and PD-L1. The Cancer research study combines topics in areas such as Cell, DNA methylation, Immune system, Atypical adenomatous hyperplasia and Targeted therapy. His Methylation study combines topics in areas such as Carcinogenesis and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger.
Molecular origins of cancer: Lung cancer
Roy S. Herbst;John V. Heymach;Scott M. Lippman;Scott M. Lippman.
The New England Journal of Medicine (2008)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge.
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits.
Cancer Research (2007)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez.
Lancet Oncology (2016)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez.
Nature Communications (2014)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann.
Cancer Discovery (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: